Immunochemical characterization of human antibodies to lymphobiastoid interferon
- 1 December 1991
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 86 (3) , 514-519
- https://doi.org/10.1111/j.1365-2249.1991.tb02962.x
Abstract
SUMMARY: Antibodies produced in recurrent respiratory papillomatosis (RRP) patients treated with Iymphoblastoid interferon (1yIKN) may neutralize antiviral activity or may only bind to 1yIFN. These antibodies were characterized for immunoglobulin class. IgG subclass. and light chain type by an indirect immunoassay. Serum dilutions were incubated on 1yIFN-coated plates and the presence of antibody detected using peroxidase-conjugated goat antibodies to each human immunoglobulin class and light chain isotype, or using MoAbs to each human IgG subclass. Neutralizing activity was measured as the inhibition of 1yIFN antiviral activity for Vervet monkey cells challenged with Semliki Forest Virus. Among antibody-positive patients, 12% produced IgM coincident with IgG, and 25% produced IgA coincident with IgG. Thus, antibody responses in patients treated with 1yIFN are not exclusively of IgG class. The predominant 1yIFN-specific subclasses were IgG1 and IgG3, which occurred in 70% and 83% of patients, respectively. An IgG4 response was detected in two patients who also had antibody of other isotypes; no IgG2 antibody was detected in any patient. Antibodies were not IgG subclass-restricted, a trend which was more pronounced in patients having neutralizing antibody than non-neutralizing antibody. Light chain molecules of 1yIFN-specific antibody were of both k and λ isotypes. with k chains occurring most frequently. Among patients having non-neutralizing antibodies, monotypic light chains occurred in 65% of the patients, whereas no patient with neutralizing antibody had monotypic light chain antibody. Sera from 599 normal human volunteers were assayed for antibody, and seven were found to be immunoreactive to 1yIFN. Only-one serum of the seven was positive for neutralizing activity.Keywords
This publication has 27 references indexed in Scilit:
- Randomized Surgical Adjuvant Trial of Interferon Alfa-n1 in Recurrent PapillomatosisJAMA Otolaryngology–Head & Neck Surgery, 1988
- Interferon alfa‐n1 (wellferon)® in juvenile onset recurrent respiratory papillomatosis: Results of a randomized study in twelve collaborative institutionsThe Laryngoscope, 1988
- Subclass distribution of IgG and IgA responses to rubella virus in manJournal of Medical Microbiology, 1986
- Immunoglobulin flexibility in complement activationImmunology Today, 1986
- Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (intron a)The American Journal of Medicine, 1986
- The Subclass Nature and Clinical Significance of the IgG Antibody Response in Patients Undergoing Allergen‐Specific ImmunotherapyAllergy, 1985
- Clinical Study of Recombinant DNA-Produced Leukocyte Interferon (Clone A) in an Intermittent Schedule in Cancer Patients2JNCI Journal of the National Cancer Institute, 1983
- ANTIBODIES TO HUMAN LEUCOCYTE INTERFERONS IN CANCER PATIENTSThe Lancet, 1983
- Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer PatientsAnnals of Internal Medicine, 1982
- Serum Concentrations of IgG Subclasses1 1This work was supported by the Swiss National Foundation for Scientific Research.Published by Elsevier ,1976